靶向胶原蛋白优化癌症免疫治疗。

IF 13.5 1区 医学 Q1 HEMATOLOGY
Yida Wang, Feng Zhang, Zhiwen Qian, Ying Jiang, Danping Wu, Lu Liu, Xin Ning, Jie Mei, Daozhen Chen, Yan Zhang
{"title":"靶向胶原蛋白优化癌症免疫治疗。","authors":"Yida Wang, Feng Zhang, Zhiwen Qian, Ying Jiang, Danping Wu, Lu Liu, Xin Ning, Jie Mei, Daozhen Chen, Yan Zhang","doi":"10.1186/s40164-025-00691-y","DOIUrl":null,"url":null,"abstract":"<p><p>Collagen in the tumor microenvironment plays diverse biological roles, from serving as the structural framework of tumors to influencing immune responses, angiogenesis, and tumor progression. Consequently, developing strategies to optimize the suppression of collagen's promotive effects on tumor growth while maintaining its inhibitory functions on tumor initiation has become a key focus of cancer research and therapy. A significant challenge remains in identifying a biomarker with both high sensitivity and specificity for cancer diagnosis. This review, therefore, highlights the substantial value and clinical relevance of collagen as a biomarker throughout cancer onset and progression. It explores the fundamental link between collagen and immunotherapeutic outcomes, further illustrating how targeting collagen-along with its interactions with tumors and immune cells-can offer more reliable predictive markers for personalized immunotherapy. This approach ultimately enables the development of more tailored and standardized treatment regimens for patients with cancer.</p>","PeriodicalId":12180,"journal":{"name":"Experimental Hematology & Oncology","volume":"14 1","pages":"101"},"PeriodicalIF":13.5000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306033/pdf/","citationCount":"0","resultStr":"{\"title\":\"Targeting collagen to optimize cancer immunotherapy.\",\"authors\":\"Yida Wang, Feng Zhang, Zhiwen Qian, Ying Jiang, Danping Wu, Lu Liu, Xin Ning, Jie Mei, Daozhen Chen, Yan Zhang\",\"doi\":\"10.1186/s40164-025-00691-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Collagen in the tumor microenvironment plays diverse biological roles, from serving as the structural framework of tumors to influencing immune responses, angiogenesis, and tumor progression. Consequently, developing strategies to optimize the suppression of collagen's promotive effects on tumor growth while maintaining its inhibitory functions on tumor initiation has become a key focus of cancer research and therapy. A significant challenge remains in identifying a biomarker with both high sensitivity and specificity for cancer diagnosis. This review, therefore, highlights the substantial value and clinical relevance of collagen as a biomarker throughout cancer onset and progression. It explores the fundamental link between collagen and immunotherapeutic outcomes, further illustrating how targeting collagen-along with its interactions with tumors and immune cells-can offer more reliable predictive markers for personalized immunotherapy. This approach ultimately enables the development of more tailored and standardized treatment regimens for patients with cancer.</p>\",\"PeriodicalId\":12180,\"journal\":{\"name\":\"Experimental Hematology & Oncology\",\"volume\":\"14 1\",\"pages\":\"101\"},\"PeriodicalIF\":13.5000,\"publicationDate\":\"2025-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306033/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental Hematology & Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40164-025-00691-y\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental Hematology & Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40164-025-00691-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

胶原蛋白在肿瘤微环境中发挥着多种生物学作用,从作为肿瘤的结构框架到影响免疫反应、血管生成和肿瘤进展。因此,制定策略,优化抑制胶原蛋白对肿瘤生长的促进作用,同时保持其对肿瘤起始的抑制功能,已成为癌症研究和治疗的重点。鉴别一种具有高敏感性和特异性的癌症诊断生物标志物仍然是一个重大挑战。因此,这篇综述强调了胶原蛋白作为一种生物标志物在癌症发生和发展过程中的重要价值和临床意义。它探讨了胶原蛋白和免疫治疗结果之间的基本联系,进一步说明了靶向胶原蛋白及其与肿瘤和免疫细胞的相互作用如何为个性化免疫治疗提供更可靠的预测标记。这种方法最终能够为癌症患者开发更有针对性和标准化的治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Targeting collagen to optimize cancer immunotherapy.

Targeting collagen to optimize cancer immunotherapy.

Targeting collagen to optimize cancer immunotherapy.

Targeting collagen to optimize cancer immunotherapy.

Collagen in the tumor microenvironment plays diverse biological roles, from serving as the structural framework of tumors to influencing immune responses, angiogenesis, and tumor progression. Consequently, developing strategies to optimize the suppression of collagen's promotive effects on tumor growth while maintaining its inhibitory functions on tumor initiation has become a key focus of cancer research and therapy. A significant challenge remains in identifying a biomarker with both high sensitivity and specificity for cancer diagnosis. This review, therefore, highlights the substantial value and clinical relevance of collagen as a biomarker throughout cancer onset and progression. It explores the fundamental link between collagen and immunotherapeutic outcomes, further illustrating how targeting collagen-along with its interactions with tumors and immune cells-can offer more reliable predictive markers for personalized immunotherapy. This approach ultimately enables the development of more tailored and standardized treatment regimens for patients with cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
12.60
自引率
7.30%
发文量
97
审稿时长
6 weeks
期刊介绍: Experimental Hematology & Oncology is an open access journal that encompasses all aspects of hematology and oncology with an emphasis on preclinical, basic, patient-oriented and translational research. The journal acts as an international platform for sharing laboratory findings in these areas and makes a deliberate effort to publish clinical trials with 'negative' results and basic science studies with provocative findings. Experimental Hematology & Oncology publishes original work, hypothesis, commentaries and timely reviews. With open access and rapid turnaround time from submission to publication, the journal strives to be a hub for disseminating new knowledge and discussing controversial topics for both basic scientists and busy clinicians in the closely related fields of hematology and oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信